The Oncology Institute, Inc. $TOI Shares Bought by FourWorld Capital Management LLC

FourWorld Capital Management LLC raised its position in The Oncology Institute, Inc. (NASDAQ:TOI) by 30.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 499,196 shares of the company’s stock after buying an additional 116,496 shares during the quarter. Oncology Institute makes up approximately 0.8% of FourWorld Capital Management LLC’s portfolio, making the stock its 13th biggest position. FourWorld Capital Management LLC’s holdings in Oncology Institute were worth $1,533,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Kestra Advisory Services LLC purchased a new position in shares of Oncology Institute during the fourth quarter worth approximately $31,000. Pekin Hardy Strauss Inc. purchased a new stake in Oncology Institute in the 4th quarter valued at $36,000. Cetera Investment Advisers raised its position in Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after purchasing an additional 4,545 shares during the last quarter. State of Wyoming purchased a new stake in Oncology Institute in the 2nd quarter valued at $37,000. Finally, R Squared Ltd acquired a new stake in Oncology Institute during the 4th quarter worth $41,000. 36.86% of the stock is owned by institutional investors and hedge funds.

Oncology Institute Stock Performance

Oncology Institute stock opened at $4.98 on Monday. The company has a market cap of $492.22 million, a P/E ratio of -13.46 and a beta of 0.36. The Oncology Institute, Inc. has a one year low of $2.32 and a one year high of $6.67. The business has a fifty day moving average of $5.11 and a two-hundred day moving average of $3.88.

Oncology Institute (NASDAQ:TOI) last issued its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. The company had revenue of $147.44 million during the quarter, compared to analysts’ expectations of $142.10 million. Sell-side analysts predict that The Oncology Institute, Inc. will post -0.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Friday, July 17th. BTIG Research upped their target price on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Lake Street Capital started coverage on shares of Oncology Institute in a research note on Monday, July 6th. They set a “buy” rating and a $10.00 price target on the stock. Finally, Needham & Company LLC raised their price objective on shares of Oncology Institute from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Oncology Institute has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Insider Activity at Oncology Institute

In other news, major shareholder Jorey Chernett bought 33,500 shares of Oncology Institute stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $4.07 per share, for a total transaction of $136,345.00. Following the acquisition, the insider owned 10,567,858 shares in the company, valued at approximately $43,011,182.06. This trade represents a 0.32% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Yale Podnos sold 23,451 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $5.38, for a total transaction of $126,166.38. Following the sale, the insider directly owned 259,527 shares in the company, valued at $1,396,255.26. This represents a 8.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have purchased a total of 113,500 shares of company stock valued at $514,405 over the last 90 days. Insiders own 4.40% of the company’s stock.

Oncology Institute Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.